Pharmacokinetics and pharmacodynamics of recombinant soluble thrombomodulin in disseminated intravascular coagulation patients with renal impairment

Shock

Volumn 37, Issue 6, 2012, Pages 569-573

  Hayakawa, Mineji ^a   Yamamoto, Hiroshi ^a   Honma, Taeko ^a   Mukai, Nobutaka ^a   Higashiyama, Asumi ^a   Sugano, Masahiro ^a   Kubota, Nobuhiko ^a   Uegaki, Shinji ^a   Sawamura, Atsushi ^a   Gando, Satoshi ^a  

^a HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

Author keywords

clearance; Disseminated intravascular coagulation; protein C; prothrombinase activity; renal dysfunction; thrombomodulin

Indexed keywords

BLOOD CLOTTING FACTOR 10A; RECOMBINANT THROMBOMODULIN;

AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG CLEARANCE; DRUG INFUSION; ENZYME ACTIVITY; FEMALE; HUMAN; KIDNEY DISEASE; MALE; OBSERVATIONAL METHOD; REPEATED DRUG DOSE;

AGED; ANTICOAGULANTS; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; HUMANS; KIDNEY DISEASES; MALE; RECOMBINANT PROTEINS; THROMBOMODULIN; THROMBOPLASTIN;

EID: 84861460182     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0b013e318252bc82     Document Type: Article

References (21)

1. Esmon CT: The interactions between inflammation and coagulation. Br J Haematol 131(4):417-430, 2005. (Pubitemid 43899639)
2. Nakashima M, Kanamaru M, Umemura K, Tsuruta K: Pharmacokinetics and safety of a novel recombinant soluble human thrombomodulin, ART-123, in healthy male volunteers. J Clin Pharmacol 38(1):40-44, 1998. (Pubitemid 28086722)
3. Tsuruta K, Kodama T, Serada M, Hori K, Inaba A, Miyake T, Kohira T: Pharmacokinetics of recombinant human soluble thrombomodulin, thrombomodulin alfa in the rat. Xenobiotica 39(2):125-134, 2009.
4. van Iersel T, Stroissnig H, Giesen P, Wemer J, Wilhelm-Ogunbiyi K: Phase I study of solulin, a novel recombinant soluble human thrombomodulin analogue. Thromb Haemost 105(2):302-312, 2011.
5. Safety and efficacy of ART-123 in subjects with sepsis and disseminated intravascular coagulation. Available at: http://clinicaltrials.gov/ct2/show/ NCT00487656. Accessed April 4, 2012.
6. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP: The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 273(2):117-123, 1995.
7. Nakashima M, Uematsu T, Umemura K, Maruyama I, Tsuruta K: A novel recombinant soluble human thrombomodulin, ART-123, activates the protein C pathway in healthy male volunteers. J Clin Pharmacol 38(6):540-544, 1998. (Pubitemid 28285229)
8. Gando S, Saitoh D, Ogura H, Mayumi T, Koseki K, Ikeda T, Ishikura H, Iba T, Ueyama M, Eguchi Y, et al.: Natural history of disseminated intravascular coagulation diagnosed based on the newly established diagnostic criteria for critically ill patients: results of a multicenter, prospective survey. Crit Care Med 36(1):145-150, 2008.
9. Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: a severity of disease classification system. Crit Care Med 13(10):818-829, 1985. (Pubitemid 15250137)
10. Vincent JL, de Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S: Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on Bsepsis-related problems[ of the uropean Society of Intensive Care Medicine. Crit Care Med 26(11): 1793-1800, 1998. (Pubitemid 28527688)
11. The ACCP/SCCM Consensus Conference Committee: American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20(6):864-874, 1992.
12. US Department of Health and Human Services Food and Drug Administration: Pharmacokinetics in patients with impaired renal function. Study design, data analysis, and impact on dosing and labeling. Guidance for Industry 1998. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM072127.pdf. Accessed April 4, 2012.
13. Tsuruta K, Yamada Y, Serada M, Tanigawara Y: Model-based analysis of covariate effects on population pharmacokinetics of thrombomodulin alfa in disseminated intravascular coagulation (DIC) patients and normal subjects. J Clin Pharmacol 51(9):1276-1285, 2010.
14. Moll S, Lindley C, Pescatore S, Morrison D, Tsuruta K, Mohri M, Serada M, Sata M, Shimizu H, Yamada K, et al.: Phase I study of a novel recombinant human soluble thrombomodulin, ART-123. J Thromb Haemost 2(10): 1745-1751, 2004. (Pubitemid 40192715)
15. Margarson MP, Soni N: Serum albumin: touchstone or totem? Anaesthesia 53(8):789-803, 1998. (Pubitemid 28391386)
16. Aman J, van der Heijden M, van Lingen A, Girbes AR, van Nieuw Amerongen GP, van Hinsbergh VW, Groeneveld AB: Plasma protein levels are markers of pulmonary vascular permeability and degree of lung injury in critically ill patients with or at risk for acute lung injury/acute respiratory distress syndrome. Crit Care Med 39(1):89-97, 2011.
17. Aibiki M, Fukuoka N, Umakoshi K, Ohtsubo S, Kikuchi S: Serum albumin levels anticipate antithrombin III activities before and after antithrombin III agent in critical patients with disseminated intravascular coagulation. Shock 27(2):139-144, 2007.
18. Mohri M: ART-123: recombinant human soluble thrombomodulin. Cardiovascular Drug Reviews 18(4):312-325, 2000.
19. Saito H, Maruyama I, Shimazaki S, Yamamoto Y, Aikawa N, Ohno R, Hirayama A, Matsuda T, Asakura H, Nakashima M, et al.: Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 5(1):31-41, 2007. (Pubitemid 44921064)
20. Mohri M, Sugimoto E, Sata M, Asano T: The inhibitory effect of recombinant human soluble thrombomodulin on initiation and extension of coagulationYa comparison with other anticoagulants. Thromb Haemost 82(6):1687-1693, 1999.
21. Reinhart K, Bayer O, Brunkhorst F, Meisner M: Markers of endothelial damage in organ dysfunction and sepsis. Crit Care Med 30(5 Suppl): S302-S312, 2002. (Pubitemid 34508007)